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Uterine leiomyoma is the most frequently occurring solid pelvic tumor in women during the reproductive
period. Magnetic resonance-guided high-intensity focused ultrasound is a promising technique for decreas-
ing menorrhagia and dysmenorrhea in symptomatic women. The aim of this study is to review the role of
Magnetic resonance-guided high-intensity focused ultrasound in the treatment of uterine fibroids in symp-
tomatic patients. We performed a review of the MEDLINE and Cochrane databases up to April 2016. The analysis
and data collection were performed using the following keywords: Leiomyoma, High-Intensity Focused
Ultrasound Ablation, Ultrasonography, Magnetic Resonance Imaging, Menorrhagia. Two reviewers independently
performed a quality assessment; when there was a disagreement, a third reviewer was consulted. Nineteen
studies of Magnetic resonance-guided high-intensity focused ultrasound-treated fibroid patients were selected.
The data indicated that tumor size was reduced and that symptoms were improved after treatment. There were
few adverse effects, and they were not severe. Some studies have reported that in some cases, additional ses-
sions of Magnetic resonance-guided high-intensity focused ultrasound or other interventions, such as myo-
mectomy, uterine artery embolization or even hysterectomy, were necessary. This review suggests that Magnetic
resonance-guided high-intensity focused ultrasound is a safe and effective technique. However, additional
evidence from future studies will be required before the technique can be recommended as an alternative
treatment for fibroids.
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’ INTRODUCTION
A uterine fibroid is a benign neoplasia originating from
smooth muscle tissue. Uterine fibroids are classified as sub-
serosal, intramural, and submucosal based on their location
within the uterus. These different types of uterine fibroids
may have diverse manifestations. The main symptoms are
intense or prolonged menstrual bleeding (menorrhagia),
dysmenorrhea, dyspareunia, adjacent organ compression
(bladder and bowel), urinary incontinence, increased abdom-
inal volume, infertility, and repeated miscarriages (1-3). Menor-
rhagia may cause anemia, which together with dysmenorrhea
and dyspareunia, has a negative effect on the quality of life
of these women. The increase in abdominal volume and
the compression of adjacent organs may affect the intestinal
and urinary habits of the patient, in addition to causing
discomfort (3).
The classic treatments for fibroids include excision of the
tumors and hysterectomy. However, such techniques may
be very costly due to the length of surgery, increased bleed-
ing risk, longer hospitalization, and possible postoperative
complications. Therefore, researchers are developing new
techniques such as magnetic resonance-guided high-intensity
focused ultrasound (MRgFUS) (4-6).
MRgFUS is a minimally invasive therapy capable of
producing necrosis by thermal coagulation of myometrial
nodules at a precise location in the uterus (4). It is primarily
used to decrease the volume of fibroids and to reduce com-
plaints about symptoms. However, in many centers, MRgFUS
is currently neither advocated nor established as an alter-
native therapy. Initial studies comprising various cohort sizes
reported significant symptom improvement in response
to MRgFUS. Even with partial results, MRgFUS has been
shown to be an efficient and minimally invasive method for
treating uterine fibroids (4-6).
Most of the studies in which MRgFUS has been used are
case studies. Therefore, it is necessary to perform a system-
atic review of the studies to better assess MRgFUS as aDOI: 10.6061/clinics/2017(10)08
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therapeutic modality for uterine fibroids in symptomatic
women during the reproductive period.
’ METHODS
A review was conducted using articles in English, Spanish
and Portuguese without publication year restriction up to
April 2016 and retrieved from the MEDLINE and Cochrane
databases. The following inclusion criteria were used:
a) studies including patients of reproductive age with uterine
fibroids; b) studies including patients with menorrhagic
cycles, dysmenorrhea, and an increase in abdominal volume;
c) the use of MRgFUS for the treatment of uterine fibroids.
The exclusion criteria were as follows: a) studies of animal
models; b) studies that included asymptomatic women;
c) narrative reviews; d) case reports; e) cost assessments of
therapeutic methods; f) comparisons of different techniques
of the MRgFUS method; g) evaluation or study of the
MRgFUS technique; h) studies with different protocols for
the use of MRgFUS; i) studies that used a non-validated
questionnaire.
Articles were retrieved using the search strategies described
in Box 1 and were grouped and structured according to the
PICO strategy (the initials for ‘‘Patient’’, ‘‘Intervention,’’
‘‘Control’’ and ‘‘Outcome’’). The search strategy is described
in Figure 1.
The references cited in the articles retrieved from the
database were also evaluated. Systematic reviews and meta-
analyses were consulted, but only the original articles were
used. Two reviewers independently assessed the quality of
the studies; when there was a disagreement, a third reviewer
was consulted. The JADAD scale was used for the critical
analysis of Randomized clinical trial.
’ RESULTS
During the investigated period, a total of 207 articles were
found in MEDLINE and 8 articles were found the in the
Cochrane database (Figure 1). After the titles and abstracts
were read and the eligibility criteria were applied, 188 articles
were excluded (incomplete reviews, case reports, studies of
therapy costs, studies in animal models, and studies of the
comparisons of the different techniques of the MRgFUS
method or studies with different protocols for the use of
MRgFUS). The remaining 19 papers were included in this
review (7-25).
The effects of MRgFUS on fibroid volume and on
the patients’ symptoms and quality of life are summarized
in Tables 1 and 2. In the 19 selected studies, patient age
ranged from 32 to 50 years, and follow-up lasted from 3 to
36 months. This review comprised case studies and one
clinical trial (24). Fibroid volume decreased in all the included
studies; however, there was a discrepancy in the percentage
reduction after MRgFUS. The decrease in fibroid volume
ranged from 9,3% to 90% (11,19), as shown in Table 1.
Most studies used assessment questionnaires that have
been validated in the literature. These assessments indicated
that MRgFUS might improve the patients’ symptoms and
quality of life (7-14,17-19,23-24). Some articles used only
the symptom severity score (SSS), which is part of the
Uterine Fibroid Symptom and Health-Related Quality of Life
Questionnaire (UFS-QOL) to assess symptom improve-
ment in patients. In the UFS-QOL, the SSS mainly analyzes
symptoms such as menorrhagia and bulk-related symptoms.
Three studies did not use validated questionnaires to eval-
uate quality of life or symptom improvement (14,20,25) or
did not administer any specific questionnaires to evaluate
patients’ symptoms and quality of life. These studies were
included only in the analysis of the fibroid volume reduction.
The decrease in the SSS ranged from 32% to 74%. Four
studies used the complete UFS-QOL and reported increases
in quality of life ranging from 20% to 47%. The only clinical
trial included in this review analyzed 109 women with
fibroids and showed a significant reduction of severe symp-
toms (51%) at 12 months of follow-up, which was statistically
significant (po0.001).
No severe complications were observed in the studies
included in the analysis. The main complaints after MRgFUS
were abdominal pain and lumbar pain, which improved
with a mild analgesic. Two studies reported abdominal pain
due to the accumulation of contrast material in the muscular
and subcutaneous layers of the abdominal wall in 9% and
11% of the patients, respectively (7,13). In some cases, the
necrotic material was expelled via the vagina after treatment
over the subsequent menstrual cycles (11). The most severe
complications occurred in a patient who developed deep
vein thrombosis and required longer hospitalization (14)
and in 2 patients who had endometritis with subsequent
hysterectomy (15).
In some studies, new interventions were required because
the patients’ symptoms persisted or worsened (8,12,15,17,21).
For these reasons, Mindjuk et al. (8) reported a 12.7% rate of
additional treatments such as hysterectomy, myomectomy, or
embolization of uterine blood vessels. In the Funaki et al. (17)
study, 1 patient underwent a hysterectomy, 5 patients under-
went a myomectomy, and 5 others underwent a repeat
MRgFUS after the primary treatment.
’ DISCUSSION
The American College of Obstetricians and Gynecologists
(ACOG) recommends that hysterectomies be included as
an option for the treatment of benign conditions such as
leiomyoma (26). Otherwise, myomectomy is the treatment of
choice (1-3). However, recovery time, prolonged hospitaliza-
tion, high rates of complications that may occur intraopera-
tively, and possible hysterectomies can be avoided. In this
systematic review, MRgFUS was evaluated and found to be
effective, promising, and safe for the treatment of benign
uterine tumors. Hence, minimally invasive techniques such
Box 1 - Databases and search strategies.
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Figure 1 - Flowchart: Selection of studies included in the review.
Table 1 - Studies assessing the decrease in fibroid volume and the necrosis volume immediately after treatment in symptomatic women.
Author and
Year of Publication
Patient Follow-up
Time
Number of
Patients
Age, Mean and
Standard Deviation
Mean Reduction in
Fibroid Volume
NPV Mean (%)
Park et al., 2014 3 months 79 43.6±4.4 23.1% 62.7±25.5
Kim et al., 2012 3 months 27 44.5±3.8 64.2% 64.2±19.9
Ikink et al., 2013 6 months 46 45.3±4.1 29% 40±22
LeBlang et al., 2010 6 months 80 44±3.2 31% 55±25
Morita et al., 2008 6 months 48 42.6±5.8 33% 60±18
Rabinovic et al., 2007 6 months 35 46.4±4.7 15% 31±23
Hindley et al., 2004 6 months 109 44.8±4.9 13.5% 25±6.0
Lenard et al., 2008 12 months 66 45.4±4.4 9.3% 16.3±13.3
Dobrotwir et al., 2012 12 months 74 42±7.0 38% 67±25
Wang et al., 2012* 24 months 78 38.2±6.4 90.1% 80±12
Funaki et al., 2009 24 months 91 40.4±4.6 39.5% 67±25
Kim et al., 2011 36 months 40 46±4.5 32% 32.1±6.2
NPV: nonperfused volume.
* Study of women with submucosal fibroids.
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as MRgFUS may be an option, but further studies with a
longer follow-up are necessary.
Since the introduction of MRgFUS and its approval by the
FDA as a therapeutic modality (2004), several studies have
been conducted and have reported symptom improvement
in leiomyoma patients (6), as discussed in this review.
The articles included in this study were mostly case series
because it is difficult to conduct double-blind controlled
studies with MRgFUS. This fact limits the design and perfor-
mance of these studies. Additionally, the technique used with
MRgFUS is very different from minimally invasive techni-
ques such as embolization of uterine arteries (27).
Patient follow-up after MRgFUS lasted at least 3 months
(7,10,13) and at most 36 months (14). Regardless of the vari-
ability in the length of follow-up, the studies under investi-
gation reported reduced fibroid volume and a reduction in
the patients’ symptoms. To assess the volume reduction, the
nonperfused volume (NPV) after MRgFUS was considered.
Only 9 of the 19 studies included in this review had an NPV
over 50%. Although higher NPVs are associated with greater
efficacy, symptom improvement was similar among the studies.
It is possible that unevaluated uterine factors occurred after
MRgFUS. Potential endometrial alterations may have a con-
siderable impact on the uterus, primarily on a woman’s
reproductive future. The studies included in this review did
not evaluate this potential impact, i.e., they did not attempt
to determine the feasibility of using the MRgFUS method in
women with a desire to have children.
The differences in the previously mentioned results may
be explained by the variety of fibroid types and the variation
in signal intensity in the MRI T2 images soon after treat-
ment (20,24). Tumors generating an MRI T2 hyposignal tend
to exhibit higher necrosis rates and, consequently, larger reduc-
tions in fibroid volume. The reason for this is still unknown,
but it seems to depend on both tumor volume and factors
such as fibroid vascularization, intramural components, lesion
density, and tumor-specific hormone expression (23).
Quality of life and obvious symptoms were assessed using
the UFS-QOL. One potential limitation of the present study is
that three of the included articles did not address variables of
intense symptoms (15,21,25). A low SSS (a component of the
UFS-QOL) indicates an improvement in symptoms, whereas
an overall low UFS-QOL score indicates an enhancement of
the patient’s quality of life. The articles in this review showed
that the use of MRgFUS favors improvements in severe
symptoms, as well as in the overall quality of life, despite the
wide range of the follow-up time and the age of the study
patients.
The SSS questionnaire primarily evaluates symptoms such
as menorrhagia; therefore, its scores are more meaningful in
studies of patients with intramural or submucosal fibroids.
Taking this into consideration, Park et al. (10) studied
9 women with subserosal fibroids whose main complaints
were mass effect and increased abdominal volume. They
concluded that there was a significant reduction in volume
and in mass effect (89%) but only a slight improvement in
the SSS.
A better quality of life and improvements in bleeding and
dysmenorrhea are also related to a larger NPV (11-13,19,23).
Stewart et al. (23), whose study included more patients than
any of the other studies in this review, analyzed 359 patients
from all the clinical trials of MRgFUS in the treatment of
fibroids and found that symptom improvement was signifi-
cant. Furthermore, after a 24-month follow-up, they con-
cluded that the SSS improvement was, on average, 6 points
larger in the group of patients with the greater NPV. The
relationship between NPV and symptom improvement may
also be explained by the association of an MRI T2 hyposignal
and a larger NPV, as found in some of the previously men-
tioned studies.
In all the studies included in the present analysis, the rates
of adverse effects and complications following MRgFUS
were low. The most common symptoms were abdominal
pain, lumbar pain, first-degree burns, and light vaginal
bleeding. The abdominal pain and lumbar pain were relieved
with a common, mild analgesic. There was also pain caused
by the accumulation of contrast material in the muscle and
subcutaneous layers of the abdominal wall (7,13). However,
neither hospitalization nor intervention were subsequently
required to treat such complications. In general, tumors are
Table 2 - Studies assessing the improvement of symptoms and the quality of life of symptomatic women.
Author and
Year of Publication
Patient
Follow-up
Time
Number of
Patients
Mean Age and
Standard Deviation
Mean
Reduction in
SSS
Increase in the Overall
UFS-QOL Score
Symptom
Improvement
NPV Mean
(%)
Park et al., 2014 3 months 79 43.6±4.4 35.6% - SIM 62.7±25.5
Park et al., 2012** 3 months 9 39.8±6.2 55.5% - SIM 66.9±10.6
Kim et al., 2012 3 months 27 44.5±3.8 35.8 - SIM 64.2±19.9
Harding et al., 2008 6 months 102 45±4.8 44.8% 33.6% SIM -
Ikink et al., 2013 6 months 46 45.3±4.1 31.8% 19.5% SIM 40±22
Mikami et al., 2008 6 months 48 45±5.2 - - SIM 47±13
Hindley et al., 2004 6 months 109 44.8±4.9 - - SIM 25±6.0
Lenard et al., 2008 12 months 66 45.4±4.4 38.8% - SIM 16.3±13.3
Dobrotwir et al., 2012 12 months 74 42±7.0 51% - SIM 67±25
Gorny et al., 2011 12 months 130 45.6±5.5 - - SIM 45.4±22.5
Stewart et al., 2006* 12 months 109 44.8±4.9 51% - SIM -
Funaki et al., 2009 24 months 91 40.4±4.6 65.5% - SIM 67±25
Wang et al., 2012 24 months 78 38.2±6.4 - 31.25% SIM 80±12
Stewart et al., 2007 24 months 359 45.4±5.0 35.6% - SIM 19.9±17.2/
21.9±18.7
Mindjuk et al., 2014 24 months 252 42.1±6.9 70% - SIM 88.7±14.4
Kim et al., 2011 36 months 40 45.98±4.52 73.7% 47.4% SIM 32.1±6.2
SSS: Symptom Severity Score.
* Clinical Trial.
** Study of women with pedunculated subserosal fibroids.
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highly vascularized and may undergo a parturition pro-
cess after necrosis. In a few cases, the necrotic material was
expelled via the vagina after treatment and disappeared after
4 menstrual cycles (11). The most severe complications were
a case of deep vein thrombosis in 1 patient, which entailed
a longer hospital stay (15), and 2 cases of endometritis requir-
ing subsequent hysterectomy (16). Cases requiring interven-
tion immediately after MRgFUS were rare. Hysterectomy,
myomectomy, or uterine artery embolization was required
for patients whose condition worsened or whose dysmenor-
rhea or hypermenorrhea relapsed.
To date, there are no randomized clinical trials that
are suitable for inclusion in a meta-analysis, which would
provide a more robust analysis. Our review suggests that
MRgFUS is an effective and promising therapeutic technique
for decreasing myoma volume and patients’ symptoms.
However, further controlled and randomized studies will be
required before MRgFUS can be recommended as an alter-
native fibroid treatment (7-25).
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